RT Journal Article
SR Electronic
T1 Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis
JF Neurology
JO Neurology
FD Lippincott Williams & Wilkins
SP e2661
OP e2673
DO 10.1212/WNL.0000000000007600
VO 92
IS 23
A1 James F. Howard, Jr
A1 Vera Bril
A1 Ted M. Burns
A1 Renato Mantegazza
A1 Malgorzata Bilinska
A1 Andrzej Szczudlik
A1 Said Beydoun
A1 Francisco Javier Rodriguez De Rivera Garrido
A1 Fredrik Piehl
A1 Mariarosa Rottoli
A1 Philip Van Damme
A1 Tuan Vu
A1 Amelia Evoli
A1 Miriam Freimer
A1 Tahseen Mozaffar
A1 E. Sally Ward
A1 Torsten Dreier
A1 Peter Ulrichts
A1 Katrien Verschueren
A1 Antonio Guglietta
A1 Hans de Haard
A1 Nicolas Leupin
A1 Jan J.G.M. Verschuuren
A1 on behalf of the Efgartigimod MG Study Group
YR 2019
UL http://n.neurology.org/content/92/23/e2661.abstract
AB Objective To investigate safety and explore efficacy of efgartigimod (ARGX-113), an anti-neonatal Fc receptor immunoglobulin G1 Fc fragment, in patients with generalized myasthenia gravis (gMG) with a history of anti-acetylcholine receptor (AChR) autoantibodies, who were on stable standard-of-care myasthenia gravis (MG) treatment.Methods A phase 2, exploratory, randomized, double-blind, placebo-controlled, 15-center study is described. Eligible patients were randomly assigned (1:1) to receive 4 doses over a 3-week period of either 10 mg/kg IV efgartigimod or matched placebo combined with their standard-of-care therapy. Primary endpoints were safety and tolerability. Secondary endpoints included efficacy (change from baseline to week 11 of Myasthenia Gravis Activities of Daily Living, Quantitative Myasthenia Gravis, and Myasthenia Gravis Composite disease severity scores, and of the revised 15-item Myasthenia Gravis Quality of Life scale), pharmacokinetics, pharmacodynamics, and immunogenicity.Results Of the 35 screened patients, 24 were enrolled and randomized: 12 received efgartigimod and 12 placebo. Efgartigimod was well-tolerated in all patients, with no serious or severe adverse events reported, no relevant changes in vital signs or ECG findings observed, and no difference in adverse events between efgartigimod and placebo treatment. All patients treated with efgartigimod showed a rapid decrease in total immunoglobulin G (IgG) and anti-AChR autoantibody levels, and assessment using all 4 efficacy scales consistently demonstrated that 75% showed a rapid and long-lasting disease improvement.Conclusions Efgartigimod was safe and well-tolerated. The correlation between reduction of levels of pathogenic IgG autoantibodies and disease improvement suggests that reducing pathogenic autoantibodies with efgartigimod may offer an innovative approach to treat MG.Classification of evidence This study provides Class I evidence that efgartigimod is safe and well-tolerated in patients with gMG.AChR=acetylcholine receptor; ADA=antidrug antibody; AE=adverse event; CI=confidence interval; Cmax=maximum observed plasma concentration; FcRn=neonatal Fc receptor; gMG=generalized myasthenia gravis; IgG=immunoglobulin G; IVIg=IV immunoglobulin; IWRS=Interactive Web Response System; MedDRA=Medical Dictionary for Regulatory Authorities; MG=myasthenia gravis; MG-ADL=Myasthenia Gravis Activities of Daily Living; MG-QoL15r=revised 15-item Myasthenia Gravis Quality of Life scale; MGC=Myasthenia Gravis Composite; MGFA=Myasthenia Gravis Foundation of America; MMRM=mixed-model repeated measures; QMG=Quantitative Myasthenia Gravis; Rac=accumulation ratio; SAE=serious adverse event; TEAE=treatment-emergent adverse event; tmax=time at maximum observed plasma concentration